Saturday, December 15, 2018 4:57:51 PM
1. https://www.insysrx.com/products/approved
2. https://www.caratherapeutics.com/pipeline-technology/our-pipeline/
3. https://www.corbuspharma.com/pipeline/overview
4. https://zynerba.com/in-development/
I like the fact that other companies are doing trials because it tells the story of the future in Pharma and if you are first to market or have the most offerings then all that follow will be graded against your pipeline,that being said I think we are in that pole position.
The OTC line aswell as the drink and NHP line will see revenue on many fronts and show Tetra to be a diversified company and if it remains whole will be worth many billions in the future and then theres the possibility of selling off a division or two to expand the real gravy train which will be the division holding the PPP001 thru PPP005 line.
A GW type market cap is closer then you think and although we have 5 times the amount of shares as GW we will have 10 times the revenue ,then theres Tilray ,look at the action that took it to $300.00 a share ,that type of feeding frenzy could very well touch our Tetra in 2020-2021.That $300.00 was US dollars.
Lets get thru Dec and enjoy all that 2019 offers.
.. comments from that other board.
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM